Midostaurin in Patients (Pts) with Newly Diagnosed FLT3-Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Autor: Maaike E Heidinga, Jörg Westermann, Valerie Heidinger, Carolin Sachs, Walter Fiedler, Thierry Medts, Bourras-Rezki Bengoudifa, Richard Stone, Yuan Cheng, Jürgen Krauter, Mark J. Levis, Jorge Sierra, Hartmut Döhner, Jacqueline Cloos, Simona Sica, Gert J. Ossenkoppele, Pau Montesinos, Rouven Müller, Giedre Koenen, Lok Lam Ngai, Yvonne J M Oussoren-Brockhoff

Publikováno v: Cloos, J J, Montesinos, P, Fiedler, W, Mueller, R, Krauter, J, Sica, S, Westermann, J, Heidinga, M E, Ngai, L L, Oussoren-Brockhoff, Y J M, Doehner, H, Levis, M, Ossenkoppele, G J, Stone, R M, Koenen, G, Bengoudifa, B-R, Cheng, Y, Medts, T, Heidinger, V, Sachs, C & Sierra, J 2021, ' Midostaurin in Patients (Pts) with Newly Diagnosed FLT3-Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial ', Blood, vol. 138 . https://doi.org/10.1182/blood-2021-148129
Blood, 138. American Society of Hematology

Background Midostaurin, a multikinase inhibitor with significant activity against FLT3, was approved in combination with chemotherapy (CT) for treatment of pts with newly diagnosed (ND) FLT3-mutated AML based on the CALGB 10603/RATIFY trial (NCT00651

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e982921b853041862d63370921b154b
https://doi.org/10.1182/blood-2021-148129

Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy

Autor: Xavier Thomas, Thomas Cluzeau, Clara Minotti, Laimonas Griskevicius, Jorge Sierra, Alessandro Rambaldi, Ollivier Legrand, Sejla Hodzic, Mario Luppi, Adriano Venditti, Firas Farkas, Pau Montesinos, Denis Caillot, Bourras-Rezki Bengoudifa, Geralyn Gilotti

Publikováno v: Blood. 136:23-24

Background: Midostaurin, a multikinase inhibitor that directly inhibits FLT3, is approved for the treatment of adult patients (pts) with newly diagnosed, FLT3-mutated AML. In the phase 3 RATIFY study (NCT00651261), younger adults (aged ≤ 60 y) who

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d1b73970b205e98b251335d2af880574
https://doi.org/10.1182/blood-2020-136083

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Autor: Paolo Corradini, Enrique M. Ocio, Krzysztof Warzocha, Tontanai Numbenjapon, Suporn Chuncharunee, Hans Salwender, Jonathan L. Kaufman, Tatiana Shelekhova, Monika Sopala, Ming Chung Wang, Darrell White, Robert L. Schlossman, Meral Beksac, Thanyaphong Na Nakorn, Jian Hou, Hermann Einsele, Bourras Rezki Bengoudifa, V. Hungria, Kwee Yong, Daryl Tan, Jesús F. San-Miguel, Meletios A. Dimopoulos, Sung-Soo Yoon, Joan Bladé, Florence Binlich, Peter Gimsing, Wiesław Wiktor Jędrzejczak, Stefano Pulini, Richard Leblanc, Andreas Günther, Wenming Chen, Je-Jung Lee, Hareth Nahi, Jamie Cavenagh, Ashraf Elghandour, Ljupco Veskovski, Lugui Qiu, Sagar Lonial, Paul G. Richardson, Javier de la Rubia, Jae Hoon Lee, Claudia Corrado, Noppadol Siritanaratkul, Philippe Moreau, Sang Kyun Sohn

Publikováno v: LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Background Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic antimyeloma activity when combined with bortezomib and dexamethasone. We aimed to compare panobinostat, bortezomib, and dexamethasone with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c31343310e4d3eb38077762a1c55a190
https://doi.org/10.1016/s1470-2045(14)70440-1

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Autor: Robert L. Schlossman, Ashraf Elghandour, Noppadol Siritanaratkul, Wiesław Wiktor Jędrzejczak, V. Hungria, Paul G. Richardson, Sung-Soo Yoon, Philippe Moreau, Jesús F. San-Miguel, Thanyaphong Na Nakorn, Jian Hou, Jae Hoon Lee, Claudia Corrado, Monika Sopala, Andreas Guenther, Florence Binlich, Hermann Einsele, Bourras-Rezki Bengoudifa, Sagar Lonial, Meletios A. Dimopoulos, Meral Beksac

Panobinostat is a potent pan-deacetylase inhibitor that affects the growth and survival of multiple myeloma (MM) cells through alteration of epigenetic mechanisms and protein metabolism. Panobinostat plus bortezomib and dexamethasone (PAN-BTZ-Dex) le

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53a38ef05d3afe9edeaea36b3d88ef0e
https://europepmc.org/articles/PMC4760132/

Estimand Framework in AML Based on a Randomized, Placebo-Controlled, Phase 3 Study Investigating the Effect of Adding Midostaurin to Standard Chemotherapy in Patients with Newly Diagnosed AML without a FLT3 Mutation

Autor: Hans Weber, Noah Berkowitz, Bourras-Rezki Bengoudifa, Insa Gathmann, Albert Hoenekopp

Publikováno v: Blood. 132:5196-5196

In the ongoing randomized, placebo-controlled, phase 3 study in patients with newly diagnosed FLT3-mutation-negative acute myeloid leukemia (AML; NCT03512197) investigating the effect of adding midostaurin to standard chemotherapy, event-free surviva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2794b4c88e7d669f6548ef0c64610544
https://doi.org/10.1182/blood-2018-99-119394